MedTrace Logo

Surveillance of Pancreatic Health After Diabetes Diagnosis

NCT06803771 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15000

Last updated 2026-03-23

No results posted yet for this study

Summary

The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes within the last 6 months.

Participants will:

* attend 3 study visits over 12 months time
* provide a blood sample at each study visit
* complete an anxiety questionnaire at each visit.

Conditions

Interventions

DEVICE

Avantect Pancreatic Cancer Test

Avantect test

Sponsors & Collaborators

  • ClearNote Health

    collaborator INDUSTRY

  • University Hospital Southampton NHS Foundation Trust

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-21
Primary Completion
2028-02-28
Completion
2029-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06803771 on ClinicalTrials.gov